secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001171843-23-004945
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus Q2 revenue $4.7M, net loss $17.1M; AB-101 clears NZ regulatory for Phase 1
--------------------------------------------------------------------------------

- Total revenue $4.7M vs $14.2M YoY on lower Qilu license revenue; net loss $17.1M ($0.10 EPS).
- Cash $163.5M; runway into Q1 2025; net cash burn guidance $90-95M for 2023.
- AB-729 (imdusiran) Phase 2a data at EASL: mean HBsAg decline ~1.6 log10; four patients reached below LLOQ.
- AB-101 (oral PD-L1) received NZ Medsafe approval for Phase 1 after FDA clinical hold; dosing starts Q3 2023.
- Melissa Rewolinski appointed to board; Karen Sims promoted to CMO; Christopher Naftzger named GC and CCO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184323004945/0001171843-23-004945-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184323004945/f8k_080223.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-004945

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer